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Calcitonin controls bone formation by inhibiting
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The hormone calcitonin (CT) is primarily known for its pharmacologic action as an inhibitor of
bone resorption, yet CT-deficient mice display increased bone formation. These findings
raised the question about the underlying cellular and molecular mechanism of CT action. Here
we show that either ubiquitous or osteoclast-specific inactivation of the murine CT receptor
(CTR) causes increased bone formation. CT negatively regulates the osteoclast expression of
Spns2 gene, which encodes a transporter for the signalling lipid sphingosine 1-phosphate
(S1P). CTR-deficient mice show increased S1P levels, and their skeletal phenotype is
normalized by deletion of the S1P receptor S1P3. Finally, pharmacologic treatment with the
nonselective S1P receptor agonist FTY720 causes increased bone formation in wild-type,
but not in S1P3-deficient mice. This study redefines the role of CT in skeletal biology,
confirms that S1P acts as an osteoanabolic molecule in vivo and provides evidence for a
pharmacologically exploitable crosstalk between osteoclasts and osteoblasts.
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O
steoporosis represents a major public health problem, not
only because of its high prevalence, but also because
osteoporotic fractures are associated with high morbidity
and mortality. At the cellular level, osteoporosis is explained by
imbalanced bone remodelling, a physiologically relevant homeo-
static process mediated through bone-resorbing osteoclasts and
bone-forming osteoblasts1. On the basis of their cellular
differences, there are two distinct therapeutic options to treat
osteoporosis, either osteoclast inhibition (anti-resorptive) or
osteoblast activation (osteoanabolic). Currently, the vast
majority of patients are medicated by anti-resorptive means,
and there is only one osteoanabolic treatment option so far, daily
injection of parathyroid hormone (PTH) or a PTH fragment2.
Since a long-term blockade of bone remodelling may have
adverse effects on skeletal integrity, one of the major goals of
skeletal research is to identify novel target proteins for
osteoanabolic medication.
One of the hormones considered to influence bone remodelling
is calcitonin (CT), which was discovered more than 50 years ago
as a calcium-lowering factor produced by thyroidal C cells3,4.
CT is proteolytically released from procalcitonin (PCT),
representing a human sepsis biomarker potentially enhancing
sepsis severity5,6. CT has been shown to exert its effects
through the CT receptor (CTR), a serpentine protein expressed
at high levels in kidney and hypothalamus7,8. In bone, CT
exclusively binds to osteoclasts, exhibiting the highest CTR-
density, and causes cessation of their activity. This anti-resorptive
effect is especially pronounced in studies employing salmon
CT, displaying a 50-fold higher potency than mammalian CT9,10.
On the basis of these findings, CT was considered to represent
the functional counterpart to PTH, which physiologically
activates bone resorption by altering gene expression in
osteoblasts.
Although the pharmacologic actions of CT have been
studied extensively, there is a marked uncertainty about its
role in mammalian physiology11,12. This is primarily based on
the fact that patients with CT deficiency following thyroidectomy
do not display the expected osteoporosis, and that bone
mineral density was found decreased in individuals with
medullary thyroid carcinoma (MTC)10,13. In addition, mice
lacking Calca, the gene encoding CT and its related family
member alpha CT-gene-related peptide (aCGRP), unexpectedly
displayed high bone mass, in contrast to mice specifically lacking
aCGRP14–16. Importantly, although bone resorption was
increased in aged Calca-deficient mice, there was a twofold
higher bone formation rate at all ages analysed suggesting that the
primary physiological function of CT is to limit osteoblast
activity. These findings did not only challenge our understanding
of CT as a bone-preserving hormone, they also raised
several questions of key significance. In addition, they suggested
that understanding the cellular and molecular mode of CT
action would help to identify novel osteoanabolic treatment
options.
To study the impact of CT on skeletal integrity, we generated a
mouse model allowing cell type-specific deletion of two Calcr
exons encoding the CT-binding site of the CTR. Here we show
that CTR inactivation in all cell types or in osteoclasts specifically
causes increased bone formation. The indirect influence of CT on
bone formation is molecularly explained by a CTR-mediated
inhibition of Spns2 expression, encoding a transporter for
sphingosine 1-phosphate (S1P), one of the previously identified
molecules potentially coupling bone formation to bone
resorption17,18. Likewise, S1P levels are increased in bones of
CTR-deficient mice, and their skeletal phenotype is normalized
by additional absence of S1P3, a S1P receptor expressed by
osteoblasts.
Results
Inactivation of the CTR specifically affects bone formation.
To understand the mechanism of CT action on bone remodelling,
we generated a floxed allele of the CTR by homologous
recombination in embryonic stem cells. As it was reported that
deletion of exons 6 and 7 from the Calcr gene causes embryonic
lethality19, we constructed a targeting vector resulting in the
insertion of loxP sites 50 of exon 6 and 30 of exon 7, respectively
(Supplementary Fig. 1a). After confirming homologous
recombination by Southern blotting (Supplementary Fig. 1b),
we removed the neomycin resistance cassette by Flp-mediated
recombination and injected embryonic stem cells carrying one
floxed Calcr allele into blastocysts to generate heterozygous mice.
These were first mated with CMV-Cre transgenic mice20, leading
to the generation of mice carrying a recombined Calcr allele,
independent of Cre expression. The subsequent mating of
Calcrþ / mice resulted in wild-type, heterozygous and Calcr-
deficient animals, which were born at the expected Mendelian
ratio (Supplementary Fig. 1c,d). Since this result did not confirm
the embryonic lethality of Calcr-deficient mice observed by
others19, it was important to demonstrate loss of a functional
CTR in our model. Immunohistochemistry confirmed the
absence of the CTR protein in kidney and hypothalamus
sections from Calcr / mice (Fig. 1a), and binding assays
employing iodinated CT demonstrated the lack of specific
binding to cultured Calcr / osteoclasts (Fig. 1b). In addition,
CT inhibited the resorptive activity of wild-type, but not of
Calcr / osteoclasts, when these cells were cultured on dentin
chips for 10 days (Fig. 1c).
After backcrossing the mutant allele into the C57Bl/6 genetic
background we analysed 12 weeks old wild-type and Calcr /
littermates for potential phenotypic abnormalities. Determination
of blood parameters demonstrated no alterations in mineral
homeostasis (Supplementary Table 1) and ruled out the existence
of hepatic (Supplementary Table 2) and renal defects
(Supplementary Table 3) in Calcr / mice, which was
confirmed by histology (Supplementary Fig. 1e). Importantly,
Calcr / mice displayed higher circulating levels of alkaline
phosphatase, suggesting increased bone formation as an under-
lying cause. Therefore, we went on to analyse the skeletal
phenotype of Calcr / mice using non-decalcified histology
followed by static and dynamic histomorphometry. Here we
observed an increased trabecular bone mass compared with wild-
type littermates, which was solely explained by increased bone
formation (Fig. 1d,e). Since osteoporosis is most common in aged
individuals, we next assessed the skeletal phenotype of Calcr /
mice at 6, 12 and 18 months of age. Compared with wild-type
littermates Calcr / mice displayed an increased trabecular
bone mass together with an elevated bone formation rate at all
ages analysed (Fig. 1f). In contrast, bone resorption was not
increased in Calcr / mice, representing an unexpected finding
as our previous analysis of aged CT-deficient mice revealed a high
bone turnover phenotype with a more than twofold increase in
bone resorption markers15.
To confirm this striking difference between the two models we
applied mCT-scanning and determined porosity of the femoral
cortex (Fig. 2a) and calvarial bone (Fig. 2b) in 18-month-old
mice. While only a moderate difference between wild-type and
Calcr / mice could be detected, we found severe cortical and
calvarial porosity in CT-deficient Calca / mice that were
maintained on the same genetic background. Since aCGRP /
mice did not display this phenotype either, we hypothesized that
the observed differences between Calcr / and Calca / mice
are explained by the fact that the latter ones additionally lack
procalcitonin (PCT), a well-established sepsis biomarker, which
has been shown to interact with receptor complexes other than
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CT6,21. To address this possibility we injected lipopolysaccharide
(LPS) onto the calvaria of 6-week-old wild-type, Calcr / ,
Calca / and aCGRP / mice and applied mCT scanning 1
week thereafter (Fig. 2c). As expected, LPS treatment led to a
significant increase in calvarial porosity in mice of all genotypes,
yet its effect was significantly more pronounced in Calca /
mice. At the histological level these differences were explained by
increased osteoclastogenesis (Fig. 2d), which led us to analyse the
effect of PCT on osteoclast formation ex vivo. Here we found that
the number of TRAP-positive multinucleated osteoclasts was
significantly reduced by PCT, and most importantly the same was
the case in Calcr / cultures (Fig. 2e). Collectively, these
findings do not only suggest that PCT can affect bone mass in a
CTR-independent manner, they also demonstrated that the major
physiological function of the CTR is to limit the activity of
osteoblasts.
The CTR in osteoclasts controls bone formation. To identify
the relevant expression site mediating the inhibitory influence of
the CTR on bone formation, we crossed Calcrfl/fl mice with
transgenic mice expressing the Cre recombinase either in osteo-
blasts (Runx2-Cre), in the hypothalamus (CamK2a-Cre) or in the
osteoclast lineage (Lysm-Cre)22–24. The specificity of the chosen
approach was confirmed by genomic PCR amplifying the
recombined allele from different tissues and bone cells
(Supplementary Fig. 2a). In addition, we performed
immunohistochemistry on hypothalamus sections (Fig. 3a) and
binding assays with cultured osteoclasts (Fig. 3b), demonstrating
that Calcrfl/fl mice carrying the CamK2a-Cre transgene lacked the
CTR only in the hypothalamus, whereas binding of iodinated
CT was decreased only in osteoclasts derived from Calcrfl/fl
mice carrying the Lysm-Cre transgene. We next analysed the






















































































































































































































Figure 1 | Inactivation of the CTR specifically increases osteoblast function. (a) Immunohistochemistry for the CTR (stained in green) in kidney and
hypothalamus (hypoth.) sections from wild-type and Calcr/ mice. Scale bars, 50mm (top) and 200mm (bottom). (b) Binding of 125I-salmon CT to
osteoclasts or osteoblasts of the indicated genotypes. The dotted red line represents nonspecific binding; n¼ 3 cultures per group. *Po0.05 versus
wild-type. Data are representative of two independent experiments. (c) Quantification of dentin resorption by wild-type and Calcr/ osteoclasts
differentiated in the absence or presence of CT; n¼ 3 cultures per group. *Po0.05 versus control. Data are representative of three independent
experiments. (d) Von Kossa/van Gieson-staining of non-decalcified spine sections from 3-month-old female wild-type and Calcr/ mice (scale bars,
1 mm). (e) Histomorphometric quantification of the trabecular bone volume per tissue volume (BV/TV), the osteoblast number per bone perimeter
(ObN/Bpm), the osteoclast number per bone perimeter (OcN/Bpm) and the bone formation rate per bone surface (BFR/BS). Concentrations of osteocalcin
and collagen degradation products (crosslaps) were measured in serum; n¼ 6 mice per group. *Po0.05 versus wild-type. (f) Histomorphometric
assessment of BV/TV, BFR/BS and serum crosslaps in 6-, 12- and 18-month-old female wild-type and Calcr/ mice, and of 6-month-old Calcrþ/
mice; n¼6 mice per group. *Po0.05 versus wild-type. All error bars indicate s.d. P values were assessed by two-tailed Student’s t-test.
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(Supplementary Fig. 2b) and 12 months (Fig. 3b) of age and
found that the trabecular bone volume was increased only in
Calcrfl/fl mice carrying the Lysm-Cre transgene. Consistent with
the results from Calcr / mice, this phenotype was fully
explained by increased bone formation, whereas bone resorption
was not affected. These findings demonstrated that the inhibitory
influence on bone formation is mediated by the CTR in
osteoclasts, which led us to study the underlying molecular
mechanisms by cell culture experiments.
CT negatively regulates S1P release from osteoclasts. We first
confirmed the absence of an endogenous defect of CTR-deficient
bone marrow cells in terms of osteoclast differentiation, as sug-
gested by the previous data (Figs 1c and 2e). More specifically, we
monitored expression of two key regulators of osteoclastogenesis,
Nfatc1 and Fos, during the course of differentiation and found no
difference between wild-type and Calcr / cultures (Fig. 4a).
Similar observations were made when the bone marrow cells were

















































































































Figure 2 | Phenotypic differences between Calcr/ and Calca / mice. (a) mCT scans of the femur from 18-month-old female Calcr/ and
Calca / mice. Scale bar, 500mm. Cortical porosity for mice of the indicated genotypes is shown on the right; n¼ 5. *Po0.05 versus wild-type. (b) mCT
scans of the calvaria from 18-month-old female Calcr/ and Calca / mice. Scale bar, 1 mm. Calvarial porosity for mice of the indicated genotypes is
shown on the right; n¼ 5. *Po0.05 versus wild-type. (c) Calvarial porosity induced by local LPS injection in 6 weeks old wild-type, Calcr/ , Calca /
and aCGRP/ mice; n¼ 5. *Po0.05 versus control. #Po0.05 versus wild-type. (d) Osteoclast numbers in wild-type and Calca / mice with or
without LPS treatment; n¼ 5. *Po0.05 versus control. #Po0.05 versus wild-type. (e) TRAP-positive multinucleated cells (TRAPþMNCs) per visual field
(VF) after differentiation of bone marrow cells with M-CSF and RANKL in the presence or absence of 108 M PCT; n¼ 3; *Po0.05 versus non-treated

























































































































Figure 3 | Control of bone formation by the CTR in osteoclasts. (a) Immunohistochemistry for the presence of the CTR in hypothalamus sections. Scale
bar, 200 mm. (b) Binding of 125I-sCT to differentiated osteoclasts derived from mice of the indicated genotypes. The dotted red line represents binding
to Calcrfl/fl osteoclasts; n¼ 3 cultures per group. *Po0.05 versus Calcrfl/fl osteoclasts. Data are representative of two independent experiments.
(c) Quantification of BV/TV, ObN/Bpm, BFR/BS, OcN/Bpm and measurement of serum crosslaps in 12-month-old female mice of the genotypes indicated
above; nZ5 mice per group. *Po0.05 versus Calcrfl/fl mice. All error bars indicate s.d. P values were assessed by two-tailed Student’s t-test.
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observe differential expression of osteogenic markers, such as
Alpl, Sp7 and Bglap (Fig. 4b). We next isolated RNA from wild-
type and Calcr / osteoclasts treated with CT for 6 h to perform
genome-wide expression analysis. This allowed us to identify at
least 29 genes regulated by CT specifically in wild-type osteoclasts
(Supplementary Fig. 3a). Our analysis revealed that the expres-
sion of well-established osteoclast markers, such as Tracp5 and
Ctsk, was not affected by CT administration, while the expression
of Calcr and Crem, the two previously known CT target genes in
osteoclasts25,26, was regulated as expected (Fig. 4c). Most
importantly, we identified Spns2 as a gene negatively regulated
by CT specifically in wild-type osteoclasts. Spns2 encodes a
transmembrane protein involved in the secretion of S1P27,28,
which has been shown to function as an osteoanabolic factor
coupling bone formation to resorption in vitro17,18,29. Since this
raised the possibility that the CTR-dependent control of bone
formation is mediated by reducing S1P release from osteoclasts,
and since other genes with a putative role in osteoclast to
osteoblast communication (Sphk1, Bmp6, Efnb2 and Sema4d)
were not differentially expressed, we focused on Spns2 as a
relevant downstream target of CT in the control of bone
formation.
Consistent with the suspected role of Spns2 in osteoclast to
osteoblast communication, we observed that its expression
increased during osteoclastogenesis of wild-type cells, in contrast
to Sphk1 and Sphk2, the two genes required for intracellular S1P
production (Fig. 4d). Likewise, immunohistochemistry on human
bone sections revealed that SPNS2 was readily detectable
in multinucleated osteoclasts at the bone surface (Fig. 4e).
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Figure 4 | CT inhibits S1P release from osteoclasts. (a) qRT–PCR expression analysis for the indicated genes during differentiation of wild-type and
Calcr/ bone marrow cells into osteoclasts; n¼ 3 cultures per group. (b) qRT–PCR expression analysis for the indicated genes during differentiation of
wild-type and Calcr/ bone marrow cells into osteoblasts; n¼ 3 cultures per group. (c) Affymetrix signal intensities (relative to control) for selected
genes in wild-type and Calcr/ osteoclasts incubated in the absence or presence of CT; n¼ 3 cultures per group. *Po0.05 versus untreated Calcrþ/þ
osteoclasts. (d) qRT–PCR expression analysis for the indicated genes during differentiation of wild-type osteoclasts; n¼4 cultures per group. *Po0.05
versus day 1. Data are representative of three independent experiments. (e) Immunohistochemistry for SPNS2 in an iliac crest biopsy section from a
skeletal-intact donor. Scale bar, 20mm. (f) Intracellular S1P concentrations in osteoclast precursors or differentiated wild-type osteoclasts incubated
with or without CT for 24 h; n¼ 3 cultures per group. *Po0.05 versus untreated osteoclasts. Data are representative of two independent experiments.
(g) qRT–PCR expression analysis for Calcr, Sphk1 and Spns2 in wild-type and Calcr/ osteoclasts incubated with CT for the indicated time; n¼4 cultures
per group. *Po0.05 versus control. Data are representative of three independent experiments. (h) Extracellular S1P concentrations in conditioned
medium of wild-type and Calcr/ osteoclast precursors (Ocl prec.) or differentiated osteoclasts incubated with or without CT for 24 h; n¼ 3 cultures
per group. *Po0.05 versus untreated osteoclasts. Data are representative of three independent experiments. All error bars indicate s.d. P values were
assessed by two-tailed Student’s t-test.
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osteoclasts, we found that intracellular S1P levels declined during
the course of osteoclastogenesis and that CT administration
significantly increased them (Fig. 4f). Likewise, quantitative PCR
with reverse transcription (qRT–PCR) confirmed that Spns2
expression is negatively regulated by short-term administration of
CT to wild-type osteoclasts, but not to Calcr / osteoclasts
(Fig. 4g). As it was previously demonstrated that protein kinase A
(PKA), protein kinase C (PKC) and phospholipase C (PLC) are
the major intracellular effectors of CTR-dependent signal-
ling25,30,31, we investigated which of these pathways is involved
in the transcriptional regulation of Spns2 by CT. Here we found
that the inhibition of Spns2 expression by CT was abrogated in
the presence of the PLC inhibitor U-73122, but not by a PKC or
PKA inhibitor, indicating an involvement of the PLC-signalling
pathway (Supplementary Fig. 3b). In addition, we found that
Spns2 protein levels were markedly decreased after 9 h of CT
administration (Supplementary Fig. 3c), thereby supporting our
conclusion that Spns2 is a direct target of CT in osteoclasts. To
demonstrate the functional consequence of this regulation, we
determined S1P levels in the medium of wild-type and Calcr /
osteoclast cultures. In both wild-type and Calcr / osteoclast
cultures extracellular S1P levels increased upon differentiation,
whereas CT administration for 24 h resulted in a significant
reduction only in wild-type cultures (Fig. 4h). Taken together,
these results suggested that the CTR controls bone formation by
reducing S1P release from osteoclasts, which led us to address the
question as to which of the five known S1P receptors32,33 is
involved in the regulation of bone formation downstream of CT.
Control of bone formation by S1P3. We next determined the
expression of S1pr1-5 in different tissues as well as in primary
bone cells by RT–PCR (Supplementary Fig. 4a) and during the
course of their differentiation by qRT–PCR (Fig. 5a). Here we
found that S1pr1 and S1pr3 were differentially expressed during
osteoblastogenesis, both increasing at early stages of differentia-
tion. Since S1pr1-deficient mice die in utero34, in contrast to
S1pr3-deficient mice, which do not display obvious
abnormalities35, we first analysed the skeletal phenotype of
S1pr3-deficient mice. Our histomorphometric analysis revealed
that bone remodelling parameters did not differ between wild-
type and S1pr3-deficient mice at 3 months of age. In contrast,
8-month-old S1pr3-deficient mice displayed osteopenia and
reduced bone formation, while bone resorption parameters
were unaffected (Fig. 5b). We additionally generated mice
lacking S1pr1 specifically in osteoblasts, but here we failed to
detect alterations in bone mass or bone remodelling parameters at
both ages (Supplementary Fig. 4b–d). These findings identified
S1P3, encoded by the S1pr3 gene, as a candidate receptor
controlling bone formation in response to S1P, which led us
to utilize the S1pr3-deficient mouse model for additional
experiments.
Here we first cultured primary calvarial osteoblasts from wild-
type and S1pr3 / mice in the presence of conditioned medium
derived from osteoclast progenitors or from osteoclasts terminally
differentiated with or without CT. After 10 days of culture we
quantified matrix mineralization and found that only conditioned
medium of osteoclasts cultured without CT caused on osteoana-
bolic effect in wild-type cultures, whereas S1pr3 / cells did not
respond (Fig. 5c). Likewise, S1P significantly increased matrix
mineralization in wild-type, but not in S1pr3 / bone marrow-
derived osteoblast cultures (Fig. 5d). Moreover, S1P treatment
resulted in a rapid phosphorylation Erk1/2 in primary calvarial
osteoblasts from wild-type, but not from S1pr3 / mice (Fig. 5e,
Supplementary Fig. 5). To analyse immediate effects on gene
expression we treated wild-type and S1pr3 / bone marrow
cells at day 10 of osteogenic differentiation with S1P for 6 h and
subsequently performed qRT–PCR for selected genes (Fig. 6a).
Similar to the effect of CT on Calcr expression in osteoclasts, S1P
negatively regulated S1pr3 expression in wild-type cultures.
Importantly, short-term S1P administration caused an S1P3-
dependent increase in the expression of Col1a1, Ibsp, and Smpd3,
all of which are involved in bone matrix production by
osteoblasts36–38, and addition of the MEK1 inhibitor PD98059
blunted the stimulatory effect of S1P on Col1a1 expression
(Fig. 6b). Taken together, these results suggested that S1P3 is one
relevant receptor acting downstream of CT to control bone
formation.
Since S1P has been shown to induce expression of the pro-
osteoclastogenic cytokine Rankl in osteoblasts, we additionally
performed qRT–PCR to assess transcription of the genes
encoding Rankl (Tnfsf11) or its decoy receptor Opg (Tnfrsf11b).
While Tnfsf11 expression was induced by S1P stimulation of
wild-type and S1pr3 / bone marrow cells, Tnfrsf11b was not
affected (Fig. 6c). These results raised the question as to why the
suspected increase of S1P release in Calcr / mice does not
amplify osteoclastogenesis. In an attempt to address this question,
we took advantage of Sgpl1 / mice, lacking S1P-lyase, an
enzyme required for S1P degradation39. Due to high extracellular
S1P levels, Sgpl1 / mice display various abnormalities and
reduced life span (29 days in average). Remarkably, however,
their bone mass was progressively increasing and approximately
doubled compared with wild-type littermates in all animals
reaching the age of 6 weeks (Fig. 6d,e). Of note, TRAP activity
staining combined with cellular histomorphometry demonstrated
increased osteoclastogenesis in Sgpl1 / mice (Fig. 6f).
Importantly, these osteoclasts were functionally active, as the
serum crosslaps concentrations were significantly increased, and
the same was the case for PICP, a biomarker of bone formation
(Fig. 6g). These findings fully confirm the osteoanabolic function
of S1P in vivo and suggest that an S1P-driven high bone turnover
is only detectable when the extracellular S1P level exceed a certain
threshold.
S1pr3-deficiency abrogates osteoanabolic influences. To analyse
if S1P is responsible for the high bone mass phenotype of
Calcr / mice, we determined S1P levels in serum and bones of
6-month-old wild-type and Calcr / littermates. Here we did
not identify differences in circulating S1P levels, yet S1P con-
centrations were significantly increased in femur and spine
extracts of Calcr / mice, and the same was the case in
Calca / mice (Fig. 7a). We next generated mice lacking both,
the CTR and S1P3, and compared their skeletal phenotype to
wild-type, Calcr / and S1pr3 / controls at 4 months of age.
Here we observed the expected increase of trabecular bone mass
and bone formation in Calcr / mice, yet this phenotype was
not present in Calcr / mice additionally lacking of S1P3
(Fig. 7b). Since it was described that daily injection of the non-
selective S1P receptor agonist FTY720 protects against
ovariectomy-induced bone loss in wild-type mice40, we further
investigated whether this effect is attributable to an S1P3-
dependent increase in bone formation. Therefore, we analysed
the skeletal phenotype of wild-type and S1pr3 / mice that
received daily vehicle or FTY720 injections for 4 weeks, starting at
the age of 3 months. FTY720 administration at a dose of
6 mg kg 1 resulted in a significantly increased trabecular bone
volume in wild-type mice, whereas S1pr3 / mice did not
respond (Fig. 7c). Most importantly, although osteoclast
parameters were not different in the six groups of mice, the
bone formation rate was significantly increased by FTY720
administration in wild-type, but not S1pr3 / mice.
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Since these results suggested that S1P3 might be an attractive
target for osteoanabolic therapy, we further assessed whether its
presence on osteoblasts is also detectable in human bone sections.
Using immunohistochemistry we found that S1P3 was detectable
not only in spine sections from wild-type mice, but also in iliac
crest biopsy sections from an individual with Paget’s disease of
bone, a condition characterized by a local increase of bone
remodelling (Fig. 7d). Taken together, our findings provide a
cellular and molecular explanation for the role of CT in
mammalian physiology and identify a physiologically relevant
coupling mechanism in bone remodelling that can be targeted for
osteoanabolic treatment of bone loss disorders (Fig. 7e).
Discussion
Our results have identified a cellular and molecular explanation
for the previously ambiguous role of CT in mammalian
physiology. They demonstrate that bone formation is controlled
by the CTR in osteoclasts, where CT reduces S1P secretion by
inhibiting Spns2 expression. In turn, the high bone mass
phenotype in mice lacking the CTR is the consequence of locally
increased S1P levels, which is best underscored by the phenotypic
rescue through additional deletion of S1P3. These findings are
important and clinically relevant for several reasons. First,
they demonstrate that the primary physiological function of
mammalian CT in bone remodelling is entirely different from its
pharmacologic action, similar to PTH, a hormone physiologically
activating osteoclastogenesis, but pharmacologically increasing
bone formation41. Second, they fully support the previously
suggested role of S1P as a factor coupling bone formation to bone
resorption, which was based on in vitro- and ex vivo-
evidence17,18,29. Third, they have identified two promising
target molecules for an osteoanabolic treatment of bone loss
disorders, and it is important to state that the CTR and S1P3 are
both serpentine receptors, representing the major class of target
proteins for drug development32,33,42.
Since CT was initially identified as a potent inhibitor of bone
resorption at high pharmacological doses, it has long been
considered as surprising that thyroidectomy does not cause
osteopenia, and that bone mineral density is even decreased in
individuals with MTC12. During the course of our study we
identified three patients with CT deficiency due to thyroiditis,
and three patients with high CT serum levels due to MTC
(Supplementary Table 4). Dual-energy X-ray absorptiometry
(DEXA) revealed high bone mineral density in patients with CT
deficiency, whereas the opposite was observed in patients with CT
excess (Supplementary Fig. 6a,b). We additionally recruited 17
previously thyroidectomized individuals (Supplementary Table 5)
to perform DEXA analyses, where we observed a significant
positive correlation between bone mineral density and time after
thyroidectomy (Supplementary Fig. 6c). These findings, despite













































































































































































Figure 5 | S1P3 controls bone formation. (a) qRT–PCR expression analysis for the indicated genes in primary osteoblasts (Obl) or osteoclasts (Ocl) at
different days of differentiation (ND, non-detectable). Data are representative of two independent experiments. (b) Quantification of BV/TV, ObN/Bpm,
BFR/BS, OcN/Bpm and measurement of serum crosslaps in 3- and 8-month-old female wild-type and S1pr3 / mice; n¼ 5 mice per group. *Po0.05
versus wild-type. (c) Quantification of mineralization in wild-type and S1pr3 / primary osteoblasts differentiated for 10 days in the presence of
conditioned medium from wild-type osteoclast precursors (Ocl prec.; control) or differentiated osteoclasts being incubated in the absence or presence of
CT; n¼ 3 cultures per group. *Po0.05 versus control. Data are representative of two independent experiments. (d) Quantification of mineralization in wild-
type and S1pr3 / primary osteoblasts differentiated for 10 days in the absence or presence of S1P; n¼ 3 cultures per group. *Po0.05 versus control.
Data are representative of two independent experiments. (e) Western Blot monitoring Erk1/2 phosphorylation in wild-type and S1pr3 / primary
osteoblasts with or without S1P treatment for 15 min (uncropped blots are presented in Supplementary Fig. 5). All error bars indicate s.d. P values were
assessed by two-tailed Student’s t-test.
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with the data obtained in mouse models, and they provide further
evidence for a physiological role of mammalian CT as an
inhibitor of bone formation. At that point it is again important to
state that many conclusions regarding the functions of CT are
based on experiments performed with salmon CT. This protein
shares only 50% sequence homology to human CT, which may
not only translate into different binding characteristics to the
CTR, but also in differential effects on bone remodelling.
Therefore, our findings do not at all question the anti-
resorptive effect of pharmacological salmon CT administration,
they only show that mammalian CT has another influence under
physiological conditions.
We and others have previously shown that mice lacking CT or
one allele of the CTR display increased bone formation14,15,19.
Albeit these data already suggested that the primary physiological
function of CT is different from its pharmacologic effect, there
were still several remaining questions43. In fact, while the
homozygous deletion of exons 6 and 7 of the Calcr gene, which
encode the CTR binding site, has been reported to cause
embryonic lethality19, a CMV-Cre-mediated deletion of the
30-Calcr exons 13 and 14 did not result in embryonic lethality
or obvious alterations of bone remodelling, which was potentially
explained by insufficient recombination44. On the basis of these
inconsistencies, it was important that we could demonstrate loss
of CTR expression and function in our mouse model by several
means, and that we could identify increased bone formation as
their only phenotype. Although we do not have a sufficient
explanation for the previously described lethality of mice lacking
the Calcr exons 6 and 7, it is important to state that one difference
between the two targeting strategies is the absence or presence of
the NeoR cassette. In fact, since there are several reports
demonstrating a phenotypic influence of such an insertion45–47,
we have applied Flp-mediated recombination to remove the NeoR
cassette before our phenotypic analysis. Our data clearly
demonstrated that the major physiological function of the
murine CTR is to limit bone formation, which led us to
address the remaining questions about the underlying cellular
and molecular mechanism.
Since the CTR is known to be present on hypothalamic
neurons and differentiated osteoclasts, and since recent evidence
has suggested that it might also be expressed by terminally
differentiated osteoblasts48, we specifically deleted the Calcr exons
6 and 7 in the hypothalamus, in osteoblasts or in cells of the
osteoclast lineage to uncover the cellular and molecular
mechanism explaining the inhibitory effect of CT on bone
formation. The subsequent skeletal analysis demonstrated that
the presence of the CTR in osteoclasts is required for regulating































































































































Figure 6 | S1P affects gene expression in osteoblasts and accelerates bone turnover. (a) qRT–PCR expression analysis for the indicated genes in
wild-type and S1pr3 / osteoblasts incubated in the absence or presence of S1P for 6 h; n¼ 3 cultures per group. *Po0.05 versus control. Data are
representative of two independent experiments. (b) qRT–PCR expression analysis for Col1a1 in wild-type osteoblasts stimulated with S1P in the absence or
presence of PD98059 as indicted; n¼ 3 cultures per group. *Po0.05 versus control. (c) qRT–PCR expression analysis for the indicated genes in wild-type
and S1pr3 / osteoblasts incubated in the absence or presence of S1P for 6 h; n¼ 3 cultures per group. *Po0.05 versus control. Data are representative
of two independent experiments. (d) Von Kossa/van Gieson-staining of non-decalcified spine sections from 6 weeks old wild-type and Sgpl1 /
mice. Scale bar, 500mm. (e) Quantification of BV/TV in 3 and 6 weeks old female wild-type and Sgpl1 / mice; nZ3 mice per group. *Po0.05 versus
wild-type. (f) TRAP activity staining reveals a high number of multinucleated osteoclasts (stained in red) in decalcified spine sections from 6 weeks
old Sgpl1 / mice. Scale bar, 50mm. Quantification of OcN/Bpm is shown on the right; n¼ 3 mice per group. *Po0.05 versus wild-type. (g) Serum
crosslaps and PICP concentrations in 6 weeks old female wild-type and Sgpl1 / mice; n¼ 3 mice per group. *Po0.05 versus wild-type. All error
bars indicate s.d. P values were assessed by two-tailed Student’s t-test.
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raised by us and others that CT inhibits bone formation through
a hypothalamic relay10,19,43. Instead, our data demonstrate that
CT and the CTR are involved in the molecular crosstalk between
osteoclasts and osteoblasts. Clinically, there are several bone
remodelling disorders where increased bone formation is
triggered by excessive osteoclastogenesis, the most evident
example being Paget’s disease of bone49–52. Molecularly, several
tissue culture experiments together with genetic evidence from
mouse models have led to the identification of candidate
molecules mediating this function, such as EphrinB2, BMP6,
Sema4d or S1P17,18,53,54.
In the light of this knowledge, we performed genome-wide
expression analysis with the aim to identify a coupling factor-
encoding gene being regulated in a CTR-dependent manner. Here
we did not observe an immediate transcriptional regulation of
theses genes by CT, and the same was the case for Sphk1. In the
context of S1P this latter finding is particularly important, as
differential Sphk1 expression during osteoclastogenesis was the
first experimental evidence for S1P as a relevant coupling factor
in bone remodelling18. Instead, we observed a CTR-dependent
negative regulation of Spns2 expression, which was potentially
important, since this gene encodes a transmembrane protein
required for S1P release from various cell types27,28,55. Our qRT–
PCR expression analysis revealed that Spns2 expression increases
during osteoclastogenesis, similar to extracellular S1P levels.
Likewise, short-term administration of CT to wild-type, but not
to Calcr / osteoclasts, caused a significant reduction of both,
Spns2 expression and extracellular S1P accumulation. Consistent
with these in vitro experiments, Calcr / mice displayed
increased S1P levels in bone extracts, and their skeletal
phenotype was normalized by the additional absence of S1P3.
Taken together, these results demonstrate that the indirect action
of CT on bone formation is explained by locally increased S1P
concentrations, thereby supporting the concept that S1P receptors
serve an osteoanabolic function.
Although we cannot fully rule out a contribution of additional
S1P receptors, our results demonstrate that S1P3 is one relevant
receptor required to promote bone formation in response to S1P.
While the lack of a bone remodelling phenotype in 3-month-old
S1pr3-deficient mice is potentially explained by functional
redundancy, most likely involving S1pr1 based on its differential
expression in osteoblasts, it was evident that S1pr3-deficiency
blunted the effects of S1P in vitro, but also in vivo in the context
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Figure 7 | S1pr3-deficiency abrogates the osteoanabolic effect caused by CTR deficiency or FTY720. (a) S1P levels in serum and bones from 6-month-
old female wild-type and Calcr/ mice, and in bones from 6-month-old Calca / mice; n¼ 5 mice per group. *Po0.05 versus wild-type controls.
(b) Quantification of BV/TV and BFR/BS in 4-month-old female mice of the indicated genotypes; n¼ 5 mice per group. *Po0.05 versus wild-type.
(c) Quantification of BV/TV, BFR/BS and OcN/Bpm in 4-month-old female mice of the indicated genotypes receiving daily injections of vehicle or FYT720
at two different doses; n¼ 6 mice per group. *Po0.05 versus vehicle-treated S1pr3þ /þ mice. #Po0.05 versus wild-type. (d) Immunohistochemistry for
S1P3 in spine sections from wild-type mice (top) and in iliac crest biopsy sections of an individual with Paget’s disease of bone (bottom). Scale bars, 25mm
(top) and 50mm (bottom). (e) Schematic representation of the proposed function of the CTR in bone formation. All error bars indicate s.d. P values were
assessed by two-tailed Student’s t-test.
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that FTY720 causes an S1P3-dependent osteoanabolic effect is
of particular interest, as this nonselective S1P receptor agonist
has already been approved for the treatment of individuals
with multiple sclerosis56,57. In a previous study, FTY720
administration (3 mg kg 1) was found to protect against
ovariectomy-induced bone loss due to a negative effect on
osteoclast attachment to the bone matrix40. Although we
principally used the same strategy of FTY720 administration, it
is important to clarify the three relevant modifications compared
with this former experiment. First, since we only observed a
trend, and not a significant increase of the trabecular bone
volume by daily injection of FTY720 at a dose of 3 mg kg 1, we
repeated the experiment with a higher dose (6 mg kg 1) to
demonstrate an osteoanabolic effect in wild-type mice. Second,
our analysis included dynamic histomorphometry, which enabled
us to identify differential effects on bone formation caused by
FTY720 administration. And third, since we applied the same
strategy to S1pr3-deficient mice, we were able to show that the
osteoanabolic effect of FTY720 administration is mediated
through S1P3.
Although these results provide an important proof of principle
for the therapeutic potential of S1P receptor stimulation in
osteoporotic individuals, they do not directly translate into
clinical applicability, since the dosage used for treatment of
multiple sclerosis is much lower (up to 5 mg per day) as
compared with the animal experiments. Importantly, however,
while it is unlikely that FTY720 itself could be applied for
osteoanabolic treatment in humans, it might be a promising
approach to develop selective S1P3 agonists and to analyse their
potential for osteoporosis therapy. The osteoanabolic potential of
S1P and its remarkable influence on bone remodelling is probably
best underscored by the phenotype of Sgpl1 / mice. These
mice have been described to display high extracellular S1P levels
causing various abnormalities and early postnatal lethality39.
Moreover, a non-quantitative analysis of their skeletal
phenotype demonstrated high bone mass, which was
interpreted as osteopetrosis, that is, osteoclast dysfunction. Our
histomorphometric analysis confirmed that the trabecular bone
mass is dramatically increased in all Sgpl1-deficient mice reaching
the age of 6 weeks (approximately 15%). Importantly, however,
the number of functionally active osteoclasts was significantly
increased towards wild-type littermates, and the same was the
case for serum PICP, indicating excessive bone formation. In
conclusion, Sgpl1-deficient mice display high bone turnover
triggering a progressive bone mass increase, which occurs despite
the existence of various organ abnormalities. These findings are in
full agreement with the suspected key role of S1P in bone
remodelling and its ability to act as an osteoanabolic molecule.
Therefore, our collective findings do not only expand our
current understanding of bone remodelling, they also identify two
serpentine receptors specifically regulating bone formation. Since
serpentine receptors represent the major class of target proteins
for currently available drugs, it is conceivable to speculate that the
development of CTR-specific antagonists and/or S1pr3-specific
agonists might be a promising approach to counteract bone loss
in osteoporosis or other skeletal disorders.
Methods
Mouse models. To obtain Calcrfl/fl mice a targeting construct was generated,
where we placed a Frt-neomycin-Frt-loxP cassette (kindly provided by G. Schuetz,
Heidelberg, Germany) 50 of exon 6 and a single loxP site 30of exon 7, the latter one
being inserted by ET recombination according to standard protocols. The construct
was electroporated into embryonic stem cells R1, which were then screened for
homologous recombination by Southern blotting following DNA digestion by
Hind III. After removal of the neomycin resistance gene by electroporating a
Flp-recombinase expression plasmid (kindly provided by G. Schuetz, Heidelberg,
Germany), the targeted embryonic stem cells were injected in C57Bl/6J blastocysts
to generate chimeric mice, which were then crossed with C57Bl/6 mice to obtain
offspring with one floxed Calcr allele. These mice were either crossed to obtain
Calcrfl/fl mice or with CMV-Cre transgenic mice, resulting in an ubiquitous
recombination within the Calcr allele, as determined by Southern blotting or PCR
genotyping using two primers flanking the loxP site between exons 7 and 8
(50-TCCTGGGCTGCTGAGAAAGTATC-30 and 50-ATGTGATTGGCTGGGCA
CTG-30) and one primer located 50of the loxP site between exons 5 and 6 (50-AAG
ACAGATGGTGAGGGCTGACTG-30). The generation and genotyping of
Calca / , aCGRP / , S1pr1fl/fl, S1pr3 / and Sgpl1 / mice has been
described previously14,34,35,39,58. The same applies for mice expressing the Cre
recombinase under the control of different promoters22–24. For the confirmation of
cell type-specific S1pr1 inactivation, a combination of primers (50-GAGCGGAGGA
AGTTAAAAGTG-30 , 50-CCTCCTAAGAGATTGCAGCAA-30 and 50-GATCCTA
AGGCAATGTCCTAGAATGGGACA-30) amplifying either the floxed or the
recombined allele. To rule out a possible influence of genetic background, all
in vivo analyses were performed with littermate controls. Although our initial
analysis of the Calcr / phenotype was done with 12-week-old male and female
mice, we used female mice for subsequent analyses with ages ranging from 3 weeks
until 18 months, as indicated in the respective figure legends. Animal care and
experimental procedures were performed with approval from the animal care
committees of the University Medical Center Hamburg-Eppendorf.
Immunological protein detection. Immunohistochemistry was performed
according to standard protocols using polyclonal antibodies against the rat CTR
(Acris), human SPNS2 (Lifespan), human S1P3 (Lifespan) or mouse S1P3 (Santa
Cruz), all diluted 100-fold. Human bone sections were derived from decalcified
iliac crest biopsies from an individual with M. Paget52, or from an autopsy case of a
skeletal-intact donor. These studies were approved by the ethics committee of the
Aerztekammer Hamburg. For immunohistochemistry the rehydrated sections were
pretreated with 0.1% trypsin for 30 min, and then incubated in 3% hydrogen
peroxide for 15 min to block endogenous peroxidase activity. Incubation with 5%
BSA for 30 min was subsequently performed to block nonspecific binding.
Immunohistochemical staining with the primary antibodies was performed
overnight at 4 C. Detection was achieved with a biotinylated secondary goat
anti-rabbit IgG (1:200, Dako Cytomation) followed by incubation with a
streptavidin/HRP (1:200, Dako Cytomation). Peroxidase activity was detected
using DAB (3,30-diaminobenzidine tetrahydrochloride) as chromogenic substrate
(Dako Cytomation). Sections were counterstained with hematoxylin, dehydrated
and mounted. For western blotting, whole cells were lysed in RIPA buffer (1%
NP-40, 1% sodium desoxycholate, 0.1% sodium dodecylsulfate, 150 mM sodium
chloride, 2 mM EDTA and 10 mM sodium phosphate) or in CHAPS extraction
buffer (50 mM Tris/Hcl pH 8.0, 150 mM NaCl, 5% glycerol, 1% CHAPS, 2 mM
EGTA, 1 mM DTT) containing a protease and phosphatase inhibitor cocktail
(Roche). Equal amounts of protein were separated on 12.5% SDS–polyacrylamide
gel electrophoresis and transferred to PVDF membranes (Hybond; GE Healthcare).
After blocking with Tris-buffered saline containing 0.1% Tween 20 and 5% nonfat
dry milk, membranes were incubated overnight at 4 C with primary antibodies at
a dilution of 1:1,000. The antibodies were directed against Spns2 (#ARP56057; Avia
Systems Biology), b-actin (#MAB1501; Millipore), phospho-Erk1/2 (#9101; Cell
Signaling Technology), or Erk1/2 (#4695; Cell Signaling Technology). Secondary
HRP-conjugated antibodies (Dako) were used at a dilution of 1:5,000.
Cell culture. Primary osteoclasts were generated as described previously59. In brief,
osteoclast precursor cells were isolated from the bone marrow of 12-week-old mice
and differentiated for 4 days in a-MEM containing 10 nM 1,25(OH)2 Vitamin D3.
For the next 6 days, they additionally received M-CSF (20 ng ml 1) and RANKL
(40 ng ml 1) to allow terminal differentiation. The conditioned medium was
collected from day 1–4 of culture (osteoclast precursor cells) or from day 7–10
of culture (mature osteoclasts). Primary osteoblasts were isolated by sequential
collagenase digestion from the calvariae of 5-day-old mice and differentiated for 10
days in the presence of 25mg ml 1 ascorbic acid and 5 mM b-glycerophosphate59.
In some cases the culture medium contained 50% of conditioned medium from
osteoclast precursor cells or mature osteoclasts (cultured either in the absence or in
the presence of 10 7 M CT for the last 4 days) as indicated. To monitor effects of
S1P on osteoblasts, bone marrow cells were differentiated for 10 days in the
presence of 25mg ml 1 ascorbic acid and 5 mM b-glycerophosphate with or
without S1P (1mM). For short-term treatment, cells were serum-starved overnight
and then stimulated with S1P (1mM) for 6 h.
Cellular assays. For binding assays mature osteoclasts were incubated for 2 h with
10 11 M 125I-salmon CT in the absence or presence of 10 8 M salmon CT. Bound
radioactivity was released by 0.5 M NaOH and quantified in a g-counter. For
resorption assays, bone marrow cells were plated on dentin slices and differentiated
as described above (with CT added during the last 4 days). After staining with
toluidine blue, the resorbed area was quantified using ImageTool software. TRAP
activity staining was performed as described previously59. In brief, after removal of
the medium and two washing steps with phosphate-buffered saline (PBS), cells
were fixed with cold methanol for 5 min. After washing and drying, they were
stained with Naphthol AS-MX-Phosphate (Sigma) for 30 min before the number of
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6215
10 NATURE COMMUNICATIONS | 5:5215 | DOI: 10.1038/ncomms6215 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
TRAP-positive multinuclear cells per well was determined. For pathway analyses
osteoclasts were pre-incubated with inhibitors of PLC (U-73122, Sigma, #U6756;
10mM), PKC (Chelerythrine chloride, Sigma, #C2932; 10 mM) or PKA (H-89,
Sigma, #B1427; 300 nM) for 2 h, followed by the stimulation with 10 7 M CT for
6 h. Likewise, osteoblasts were pretreated with an Erk inhibitor (PD98059, Cell
Signaling Technology #9900, 50 mM) for 2 h before stimulation with 10 6 M S1P
for 6 h. For the assessment of matrix mineralization in primary osteoblast cultures,
cells were stained after von Kossa, and the mineralized area was quantified using
ImageTool software. For alizarin red staining, cells were incubated with 40 mM
alizarin red staining solution (pH 4.2) for 10 min at room temperature after fixation
in 90% ethanol. To quantify alizarin red incorporation cells were washed with PBS
and fixed in 90% ethanol for 1 h. After washing twice with distilled water, cells were
stained with alizarin red S solution (40 mM, pH 4.2) for 10 min. Following
additional washing steps with distilled water, the cell-bound alizarin red was
dissolved in 10% acetic acid. After incubation for 30 min at room temperature and
10 min at 85 C, the supernatant of a subsequent centrifugation step was
neutralized with 10% ammonium hydroxide solution and the absorbance was
measured at 405 nm.
Biochemical assays. Analysis of mineral homeostasis, kidney function and
determination of metabolic and hepatic parameters was carried out in the German
Mouse Clinic as described60. All parameters were determined with a Beckman-
Coulter AU 480 autoanalyzer, with the excecption of glycerol, which was measured
using a kit from Randox Laboratories (Krefeld, Germany). Enzyme-linked
immunosorbent assay was used to measure concentrations of collagen degradation
products (Crosslaps, IDS), osteocalcin (Biomedical Technologies) and PICP
(USCN Life Science). S1P concentrations were determined following HPLC
analysis with all samples being collected in silicone-coated vessels61. The samples
were transfered into siliconized glass tubes, internal standard was added and lipids
were extracted by the addition of chloroform and methanol/HCl (99.8:0.2 v/v) after
prior alkalization by 3 N NaOH. The mixture was centrifuged (300 g, 5 min) to
obtain the alkaline aqueous phase containing S1P. The organic phase was re-
extracted with methanol, 1 N NaCl and 3 N NaOH. The combined aqueous phases
were acidified by adding concentrated HCl and extracted twice with chloroform.
The resulting organic phases were combined and evaporated by a vacuum system.
The dried lipids were redissolved in methanol. Sample analyses were performed by
rapid-resolution liquid chromatography–tandem mass spectrometry using an
Agilent 1200 Series binary pump, a degasser and an autosampler (Agilent
Technologies, Böblingen, Germany). A quadrupole time-of-flight 6530 mass
spectrometer (QTOF) equipped with Jet-Stream technology operating in the
positive electrospray ionization mode was used for detection (Agilent
Technologies). High-purity nitrogen for the mass spectrometer was produced by a
nitrogen generator (Parker Balston, Maidstone, UK). Chromatographic separations
were obtained using a Waters X-Bridge C18 separation column (4.6 mm 150 mm,
3.5 mm particle size, 138 Å pore size) with a Waters X-Bridge C18 guard column
(4.6 20 mm; Waters). We chose a binary solvent system with gradient elution
consisting of eluent A (water/formic acid; 100:0.1 v/v); and eluent B (acetonitril/
tetrahydrofuran/formic acid; 50:50:0.1 v/v); and a flow rate of 0.5 ml min 1 over
15 min. Mass spectrometric measurements were conducted using the following ion
source conditions and gas settings for positive liquid chromatography–tandem
mass spectrometry: sheath gas temperature¼ 300 C; sheath gas flow¼ 9 l min 1;
nebulizer pressure¼ 30 p.s.i.g.; drying gas temperature¼ 300 C; drying gas
flow¼ 8 l min 1; capillary voltage¼ 5,400 V; fragmentor voltage¼ 200 V; nozzle
voltage¼ 2,000 V; and collision energy¼ 15 V. Quantification was performed using
MassHunter Software (Agilent Technologies). A calibration curve of analyte
concentration was performed from 1–150 pmol and constructed by linear fitting
using the least squares linear regression calculation. The resulting slope of the
calibration curve was then used to calculate the concentration of the respective
analyte in the unknowns.
Skeletal analysis. Before their skeletal analysis all mice were injected twice with
calcein (30 mg kg 1 body weight) 9 and 2 days before sacrifice, which allowed a
quantification of the bone formation rate by dynamic histomorphometry62. The
dissected skeletons were fixed overnight in 4% formalin and then transformed into
80% ethanol, before an initial analysis by contact Xray was performed using a
Faxitron Xray cabinet. The mCT scanning was performed using a Scanco mCT 40
applying 55 kV, 145mA and 200 ms integration time. Cortical bone was delineated
and evaluated automatically using the image analysis algorithm provided by the
manufacturer. The specific region for analysis of cortical thickness was a 1-mm
thick section of the central diaphysis. Bone mineral density in patients, after
obtaining informed consent, were measured in spine and both femora using DEXA
(GE Lunar Prodigy DFþ 14622). In a subset of individuals structural bone
parameters were determined in the left radius using high-resolution peripheral
quantitative computed tomography (Scanco Medical xtremeCT). All blood
parameters were determined by the Department of Clinical Chemistry.
Exclusion criteria for the patient study were clinically apparent hypo- or
hyperparathyroidism, Paget’s disease of bone, impaired renal function,
malignancies and metastatic bone disease, and bisphosphonate or teriparatide
treatment.
Histology. Non-skeletal organs were histologically analysed in the German Mouse
Clinic as described60. All organs were fixed in 4% buffered formalin before being
embedded into paraffin. Sections of 2 mm thickness were stained with haematoxylin
and eosin according to standard protocols. For bone-specific analyses, dissected
skeletons were fixed in 3.7% PBS-buffered formaldehyde for 18 h and then
transferred into 80% ethanol. Vertebral bodies L1 to L4 were dehydrated in
ascending alcohol concentrations, before they were embedded into
methylmethacrylate. Sections of 4 mm thickness were cut in the sagittal plane using
a Microtec rotation microtome. These were stained by von Kossa/van Gieson
(for static hisotmorphometry) and toluidine blue (for cellular histomorphometry)
staining procedures as described62. To determine the bone formation rate, all mice
were injected twice with calcein 9 and 2 days before being killed. Static, cellular and
dynamic histomorphometry at trabecular bone surfaces was carried out according
to the guidelines of the American Society for Bone and Mineral Research63 using
an OsteoMeasure system (Osteometrics Inc., USA). TRAP activity staining was
performed on decalcified sections using Naphthol AS-MX-Phosphate (Sigma) and
Fast Red Violet LB salt (Sigma) in 40 mM acetate buffer (pH 5).
Mice treatment. For induction of calvarial porosity, anaesthetized mice were
injected with 10 mg kg 1 LPS (Escherichia coli O111:B4) onto their calvariae
subcutaneously. After 6 days mice were killed and calvariae subjected to mCT
analyses as described above. For quantification of the porosity the Axiovision
software (Carl Zeiss) was used, while osteoclasts number was determined
after TRAP activity staining as described above. Treatment of wild-type and
S1pr3-deficient mice with FTY720 was performed in accordance to previous
study40. More specifically 3-month-old mice received daily intraperitoneal
injections of FTY720 (3 mg kg 1 or 6 mg kg 1) or vehicle (PBS containing 5%
acidified DMSO and 30% BSA). After 4 weeks of treatment, the mice were
analysed for their skeletal phenotype as described above.
Expression analysis. RNA was isolated using the RNeasyMini kit (Qiagen). For
genome-wide expression analysis, 5 mg of RNA were used for first-strand cDNA
synthesis. For Gene Chip hybridization, the fragmented cRNA was incubated in
hybridization solution at 45 C for 16 h, before the Gene Chips (Affymetrix MG
430 2.0) were washed using the Affymetrix Fluidics Station 450. Microarrays were
scanned with the Affymetrix Gene Chip Scanner 7G, and the signals were pro-
cessed using GCOS(Affymetrix). The gene expression data have been deposited in
GEO under accession code GSE60761. For RT–PCR expression analysis, 1 mg of
RNA was reversed transcribed using SuperScriptIII (Invitrogen) according to
manufacturer’s instructions. Gene-specific primers were used to amplify fragments
of S1pr1 (50-GGCTTATCTGGTCCCTCCTC-30and 50-CTTTGGCCTCAGCAA
ATAGC-30), S1pr2 (50-CCCCCTTCCATAAACAACCT-30and 50-CCCATACTGC
CTCACCTGAT-30), S1pr3 (50-TCTGCTTTCACACAACAGCC-30and 50-GCAA
GTAGCCAAGGTTGCTC-30), S1pr4 (50-GCAGAAGTCTCCACGTCCTC-30and
50-GCTGAGTGACCGAGAAGTCC-30), S1pr5 (50-TATGGCTGCAGCAGAA
ATTG-30and 50-TTCCTCTGTAGCCAGCCACT-30), and Gapdh (50-GACATCAA
GAAGGTGGTGAAGCAG-30and 50-CTCCTGTTATTATGGGGGTCTGG-30),
respectively. For qRT–PCR expression analysis, 1 mg of RNA was reversed tran-
scribed using SuperScriptIII (Invitrogen) according to manufacturer’s instructions.
qRT–PCR analysis (with Gapdh as internal control) was performed using prede-
signed TaqMan gene expression assays (Applied Biosystems), with the exception of
S1pr2, where qRT–PCR was performed using SYBR green (50-CGCAGGCTGGA
GCTTAGGGC-30 and 50-GCAGGAGCTGGGTGAGCTGC-30).
Statistical analysis. The number of samples was chosen according to established
standards providing sufficient statistical power to enable the detection of
biologically relevant differences in animal models. Mouse data were analysed by
two-tailed Student’s t-test using Excel software. All data are reported as mean±s.d.
Human data were analysed using IBM SPSS Statistics 20. Po0.05 was considered
statistically significant.
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